486 related articles for article (PubMed ID: 34131315)
1. The implications of IDH mutations for cancer development and therapy.
Pirozzi CJ; Yan H
Nat Rev Clin Oncol; 2021 Oct; 18(10):645-661. PubMed ID: 34131315
[TBL] [Abstract][Full Text] [Related]
2. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
Gunn K; Losman JA
Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Clark O; Yen K; Mellinghoff IK
Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
6. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
7. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.
Han S; Liu Y; Cai SJ; Qian M; Ding J; Larion M; Gilbert MR; Yang C
Br J Cancer; 2020 May; 122(11):1580-1589. PubMed ID: 32291392
[TBL] [Abstract][Full Text] [Related]
8. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Waitkus MS; Diplas BH; Yan H
Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Rakheja D; Fuda F; Vandergriff T; Boriack R; Medeiros BC; Frankel AE; Chen W
Hum Pathol; 2015 Feb; 46(2):322-6. PubMed ID: 25481493
[TBL] [Abstract][Full Text] [Related]
11. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.
Krell D; Mulholland P; Frampton AE; Krell J; Stebbing J; Bardella C
Future Oncol; 2013 Dec; 9(12):1923-35. PubMed ID: 24295421
[TBL] [Abstract][Full Text] [Related]
12. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.
Hvinden IC; Cadoux-Hudson T; Schofield CJ; McCullagh JSO
Cell Rep Med; 2021 Dec; 2(12):100469. PubMed ID: 35028610
[TBL] [Abstract][Full Text] [Related]
13. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.
Romanidou O; Kotoula V; Fountzilas G
Cancer Genomics Proteomics; 2018; 15(5):421-436. PubMed ID: 30194083
[TBL] [Abstract][Full Text] [Related]
14. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Guilhamon P; Eskandarpour M; Halai D; Wilson GA; Feber A; Teschendorff AE; Gomez V; Hergovich A; Tirabosco R; Fernanda Amary M; Baumhoer D; Jundt G; Ross MT; Flanagan AM; Beck S
Nat Commun; 2013; 4():2166. PubMed ID: 23863747
[TBL] [Abstract][Full Text] [Related]
16. Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Leca J; Fortin J; Mak TW
Curr Opin Biotechnol; 2021 Apr; 68():181-185. PubMed ID: 33360716
[TBL] [Abstract][Full Text] [Related]
17. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Dang L; Su SM
Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
